company background image
4571 logo

NANO MRNALtd TSE:4571 Stock Report

Last Price

JP¥140.00

Market Cap

JP¥9.9b

7D

2.2%

1Y

-22.2%

Updated

30 Jan, 2025

Data

Company Financials

4571 Stock Overview

Researches, develops, produces, and sells pharmaceuticals using micellar nanoparticles technology in Japan. More details

4571 fundamental analysis
Snowflake Score
Valuation1/6
Future Growth0/6
Past Performance0/6
Financial Health5/6
Dividends0/6

My Notes

Capture your thoughts, links and company narrative

NANO MRNA Co.,Ltd. Competitors

Price History & Performance

Summary of share price highs, lows and changes for NANO MRNALtd
Historical stock prices
Current Share PriceJP¥140.00
52 Week HighJP¥230.00
52 Week LowJP¥134.00
Beta0.35
1 Month Change-4.76%
3 Month Change-16.17%
1 Year Change-22.22%
3 Year Change-40.43%
5 Year Change-49.82%
Change since IPO-53.33%

Recent News & Updates

Is NANO MRNALtd (TSE:4571) Weighed On By Its Debt Load?

Dec 20
Is NANO MRNALtd (TSE:4571) Weighed On By Its Debt Load?

Recent updates

Is NANO MRNALtd (TSE:4571) Weighed On By Its Debt Load?

Dec 20
Is NANO MRNALtd (TSE:4571) Weighed On By Its Debt Load?

Is NANO MRNALtd (TSE:4571) A Risky Investment?

Jul 18
Is NANO MRNALtd (TSE:4571) A Risky Investment?

Shareholder Returns

4571JP BiotechsJP Market
7D2.2%0.8%1.4%
1Y-22.2%15.7%7.4%

Return vs Industry: 4571 underperformed the JP Biotechs industry which returned 15.7% over the past year.

Return vs Market: 4571 underperformed the JP Market which returned 7.4% over the past year.

Price Volatility

Is 4571's price volatile compared to industry and market?
4571 volatility
4571 Average Weekly Movement3.8%
Biotechs Industry Average Movement8.1%
Market Average Movement3.5%
10% most volatile stocks in JP Market7.4%
10% least volatile stocks in JP Market1.8%

Stable Share Price: 4571 has not had significant price volatility in the past 3 months compared to the JP market.

Volatility Over Time: 4571's weekly volatility (4%) has been stable over the past year.

About the Company

FoundedEmployeesCEOWebsite
199618Shiro Akinagawww.nanomrna.co.jp

NANO MRNA Co.,Ltd. researches, develops, produces, and sells pharmaceuticals using micellar nanoparticles technology in Japan. The company’s pipeline products include RUNX1 (mRNA) for the treatment in the area of tissue generation and vaccines; and NC-6100 PRDM14 (siRNA), which is in phase I clinical trials for the treatment of breast cancer.

NANO MRNA Co.,Ltd. Fundamentals Summary

How do NANO MRNALtd's earnings and revenue compare to its market cap?
4571 fundamental statistics
Market capJP¥9.88b
Earnings (TTM)-JP¥821.00m
Revenue (TTM)JP¥51.00m

193.8x

P/S Ratio

-12.0x

P/E Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
4571 income statement (TTM)
RevenueJP¥51.00m
Cost of RevenueJP¥9.00m
Gross ProfitJP¥42.00m
Other ExpensesJP¥863.00m
Earnings-JP¥821.00m

Last Reported Earnings

Sep 30, 2024

Next Earnings Date

Feb 14, 2025

Earnings per share (EPS)-11.63
Gross Margin82.35%
Net Profit Margin-1,609.80%
Debt/Equity Ratio36.2%

How did 4571 perform over the long term?

See historical performance and comparison

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2025/01/30 22:16
End of Day Share Price 2025/01/30 00:00
Earnings2024/09/30
Annual Earnings2024/03/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

NANO MRNA Co.,Ltd. is covered by 3 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Kiyokazu YamazakiIchiyoshi Research Institute Inc.
Hironoshin NomuraMizuho Securities Co., Ltd.
Pravin GondhaleVirtua Research Inc.